Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233558 · ClinicalTrials.gov registry record · Phase 4
Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis
A Phase 4 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT00233558 is a Phase 4 study that was terminated before completion, run by Abbott. The registered enrollment target is 160 participants.
The verdict
NCT00233558, a Phase 4 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX
Interventions
- DRUG methotrexate
- DRUG adalimumab (up to 9 months exposure)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233558
The ClinicalTrials.gov registry entry for NCT00233558 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which methotrexate is the first listed.
NCT00233558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233558 about?
NCT00233558 is a clinical study titled "Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis". The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX
What is the current status of trial NCT00233558?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2005-06.
What interventions are being tested in trial NCT00233558?
The interventions under investigation include: methotrexate (DRUG), adalimumab (up to 9 months exposure) (DRUG).
Who is sponsoring clinical trial NCT00233558?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.